Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE IB/II CLINICAL TRIAL OF SYH2051 IN COMBINATION WITH IRINOTECAN LIPOSOME FOR THE TREATMENT OF ADVANCED SOLID TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase Ib/II clinical trial of SYH2051 (the "**Product**") developed by the Group in combination with irinotecan liposome for the treatment of advanced solid tumours has been officially initiated at the first centre in China.

The Product is a highly selective ataxia-telangiectasia mutated ("**ATM**") protein kinase inhibitor, with a registration classification of Class 1 chemical drug. The Product selectively inhibits the activity of ATM kinase, a core component of the cellular deoxyribonucleic acid ("**DNA**") damage repair system, thereby blocking DNA damage repair in tumour cells.

The clinical trial initiated is a multi-centre, open-label Phase Ib/II clinical trial. It is planned to enrol patients with advanced solid tumours, and is designed to evaluate the safety and efficacy of the Product in combination with liposome irinotecan. Currently, the recruitment and screening of participants for the clinical trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 16 November 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.